[First description of ALK-positive NSCLC in a heart transplant patient].

Thoracooncological treatment under preexisting immunosuppression as in transplant patients is challenging. On the one hand, chemotherapy might potentiate infectious complications. On the other hand, checkpoint inhibitors are not effective in immunosuppressed patients. There are no reports about treatment of driver mutation among transplant patients. ALK translocation is a rare driver mutation in non-small cell lung cancer. This is a case report about treatment of a heart transplanted patient with ALK-positive non-small cell lung cancer.